ClinicalTrials.gg
CompletedNCT02476058Updated Apr 27, 2025

A Safety, Efficacy and Biomarker Study of JNJ-42847922 in Participants With Major Depressive Disorder

A Phase 1 interventional study of JNJ-42847922 and Diphenhydramine in Major Depressive Disorder, sponsored by Janssen-Cilag International NV. Completed at 7 sites in 3 countries. Open to participants aged 18 Years to 64 Years. Per ClinicalTrials.gov, last updated 2025-04-27.

Sponsored by Janssen-Cilag International NV (part of Johnson & Johnson) · Phase 1, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
48
Allocation
Randomized
Ages
18 Years to 64 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 12 studies testing seltorexant in Depressive Disorder, Major — 2 open to participants now, 2 under way, 2 of them phase 3. seltorexant · Depressive Disorder, Major.

Enrollment
10th of 12
48 · median 176
Started
2015
the only one that year
Phase 1
5 of 12
none open now
Registered
2nd of 12
by date
Lead sponsor
1 of 12
Janssen-Cilag International NV

Among the 12 studies testing seltorexant in Depressive Disorder, Major, this one is the 10th largest by enrollment, is the only one that started in 2015, is one of 5 in phase 1, and was the 2nd registered.

Depressive Disorder, Major

3,048 studies on the registry are indexed under Depressive Disorder, Major; 593 are open to participants now.

Browse Depressive Disorder, Major studies →

Open to participants now

2 of the 12 studies testing seltorexant in Depressive Disorder, Major are open now, in 12 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 2 open studies →

About seltorexant

No approval found in the FDA or EMA files read. How studies give it is on its page →

Who these studies take

Of the 414 Depressive Disorder, Major studies recruiting now, 93 (22%) set no upper age limit and 294 (71%) stop at 75 or younger; 55 take children under 18; 99 take healthy volunteers.

This study: 18 Years to 64 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 12 studies testing seltorexant in Depressive Disorder, Major, or all of them as a file.
02

Study summary

The purpose of this study is to evaluate the safety and tolerability of JNJ-42847922 in participants with Major Depressive Disorder (MDD).

Read the detailed description

This will be a multi-center (when more than one hospital works on a medical research study), randomized (study medication assigned to participants by chance), double-blind (neither the researchers nor the participants know what treatment the participant is receiving) and placebo-controlled (an inactive substance; a pretend treatment [with no drug in it] that is compared in a clinical trial with a drug to test if the drug has a real effect) study. This study will consist of an eligibility screening examination (between 28 days and 1 day prior to the first dose administration), a parallel group treatment phase of 10 days or 4 weeks, and a follow-up period of 2 weeks including 2 follow-up visits. The duration of study will be 12 months. Participants will be randomly assigned to receive either JNJ-42847922, Diphenhydramine or Placebo. Participants' safety will be monitored throughout the study.

03

Conditions studied

  • Major Depressive Disorder

Keywords

  • Major Depressive Disorder
  • JNJ-42847922
  • Diphenhydramine
  • Placebo
04

Who can participate

Ages eligible
18 Years to 64 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Before randomization, a woman must be either: 1) Not of : ; permanently sterilized; or otherwise be incapable of pregnancy. 2) Of childbearing potential and practicing a highly effective method of consistent with local regulations regarding the use of birth control methods for participants participating in clinical studies: example, established use of oral, injected or implanted hormonal methods of contraception; placement of an intrauterine device (IUD) or intrauterine system (IUS) in combination with barrier methods: condom with spermicidal foam/gel/film/cream/suppository or occlusive cap with spermicidal foam/gel/film/cream/suppository; male partner sterilization; true abstinence. Women must agree to continue using these methods of contraception throughout the study and for at least 3 months after receiving the last dose of study medication
  • Participant (BMI) must be between 18 and 30 kilogram per square meter (kg/m2) inclusive
  • Participant must meet the -IV (DSM-IV) or 5 diagnostic criteria for major depressive disorder (MDD) without psychotic features, and confirmed by the Mini International Neuropsychiatric Interview (MINI) 6.0; Participant must have an Inventory of Depressive Symptomatology- Clinician rated-30 (IDS-C30) total score greater than or equal to (>=) 30; Participant is either currently antidepressant naive or currently being treated with a maximum of two concurrent antidepressants. If the subject is currently treated with antidepressants, they have to be given at an optimal dose and for at least 4 weeks, but not longer than 24 weeks with a suboptimal response
  • A man who is sexually active with a woman of childbearing potential and has not had a vasectomy must agree to use a barrier method of birth control e.g., either condom with spermicidal foam/gel/film/cream/suppository or partner with occlusive cap (diaphragm or cervical/vault caps) with spermicidal foam/gel/film/cream/suppository, and all men must also not donate sperm during the study and for 3 months after receiving the last dose of study drug
  • Participant must be willing and able to adhere to the prohibitions and restrictions specified in this protocol

Exclusion criteria

Exclusion Criteria:

  • Women who is pregnant or breast feeding
  • Participant has a history of within 5 years before screening (exceptions are squamous and basal cell carcinomas of the skin and carcinoma in situ of the cervix, or malignancy that in the opinion of the investigator, with concurrence with the sponsor's study responsible physician, is considered cured with minimal risk of recurrence)
  • Participant has a primary DSM diagnosis of general anxiety disorder (GAD), panic disorder, obsessive compulsive disorder (OCD), posttraumatic stress disorder (PTSD), anorexia nervosa, or bulimia nervosa. Subjects with comorbid GAD, social anxiety disorder (SAD), or panic disorder for whom MDD is considered the primary diagnosis are not excluded
  • Participant has a length of current major depressive episode (MDE) >24 months despite adequate treatment
  • Participant has failed more than 2 treatments with a different pharmacological mode of action despite an adequate dose and duration during a previous, or the current depressive episode
Terms in these criteria, in plain language(6)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Postmenopausal

Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

DSM diagnostic criteria

The American Psychiatric Association’s manual of mental health diagnoses. DSM-5 (2013, revised as DSM-5-TR in 2022) replaced DSM-IV, and some studies still name the older edition. “Meets DSM criteria for …” means diagnosed by that edition’s diagnostic criteria, usually by a clinician in an interview.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Care provider)
Enrollment
48 participants (actual)

Study arms

  • Experimental
    JNJ-42847922

    JNJ-428479, 20 milligram (mg) capsule, orally, once daily, at bedtime for 10 days in women of childbearing potential (WOCBP) or for 4 weeks in all other participants.

    Drug: JNJ-42847922

  • Experimental
    Diphenhydramine

    Diphenhydramine 25 mg capsule, orally, once daily, at bedtime for 10 days in women of childbearing potential (WOCBP) or for 4 weeks in all other participants.

    Drug: Diphenhydramine

  • Placebo comparator
    Placebo

    Matching placebo (capsules containing neutral pellets), orally, once daily, at bedtime for 10 days in women of childbearing potential (WOCBP) or for 4 weeks in all other participants.

    Drug: Placebo

Interventions

  • JNJ-428479, 20 milligram (mg) capsule, orally, once daily, at bedtime for 10 days in women of childbearing potential (WOCBP) or for 4 weeks in all other participants.

  • Diphenhydramine 25 mg capsule, orally, once daily, at bedtime for 10 days in women of childbearing potential (WOCBP) or for 4 weeks in all other participants.

  • DrugPlacebo

    Matching placebo (capsules containing neutral pellets), orally, once daily, at bedtime for 10 days in women of childbearing potential (WOCBP) or for 4 weeks in all other participants.

06

What researchers measure

Primary outcomes

  1. Number of Participants With Adverse Events (AEs) or Serious Adverse Events (SAEs)

    An AE is any untoward medical occurrence in a participant who received study drug without regard to possibility of causal relationship. An SAE is an AE resulting in any of the following outcomes or deemed significant for any other reason: death; initial or prolonged inpatient hospitalization; lifethreatening experience (immediate risk of dying); persistent or significant disability/incapacity; congenital anomaly.

    Time frame: Screening until follow-up phase (up to 12 months)

Secondary outcomes

  1. Participants Leeds Sleep Evaluation Questionnaire (LSEQ) Score

    The LSEQ comprises 10 self-rating 100 millimeter (mm)-line analogue questions regarding changes in the quality of sleep and early morning behavior, following any given intervention. Scores range between 0 and 100. Scores beneath 50 indicate better sleep.

    Time frame: Day 2, 11, 29, 31, 42

  2. Computerized Cognitive Test Battery: ISLT (Verbal Learning and Memory) Test

    The ISLT is a measure of verbal learning and memory and uses a well-validated list-learning paradigm. The task is administered using a computer. High frequencies, high imagery, concrete nouns (items from a shopping list) are read to the participant by the test supervisor at the rate of one word every two seconds. Once the \[12\] words have been read, the participant is asked to recall as many of the words as he/she can as quickly as possible. The test supervisor uses a mouse or stylus to mark the words recalled by the participant on the computer screen. When the participant can recall no more words, the same list is read a second time. The test supervisor records the words recalled by the participant on this trial. This is then repeated a third time. The delayed recall condition requires the participant to recall the words from the list after a delay without having the list read again.

    Time frame: Day 1, 2 , 5, 6, 10 and 11

  3. Computerized Cognitive Test Battery: Detection (DET) Test

    Simple reaction time task measuring processing speed; mean of the log10 transformed reaction times for correct responses (lower score = better performance).

    Time frame: Day 1, 2 , 5, 6, 10 and 11

  4. Computerized Cognitive Test Battery: Identification (IDN) Test

    Choice reaction time paradigm measuring attention; mean of the log10 transformed reaction times for correct responses (lower score = better performance).

    Time frame: Day 1, 2 , 5, 6, 10 and 11

  5. Computerized Cognitive Test Battery: One Back (OBK) Test

    Working memory measure; mean of the log10 transformed reaction times for correct responses (lower score = better performance).

    Time frame: Day 1, 2 , 5, 6, 10 and 11

  6. Computerized Cognitive Test Battery: Groton Maze Learning Test (GMLT)

    Executive function measure; total number of errors made in attempting to learn the same hidden pathway on five consecutive trials during a single session (lower score = better performance).

    Time frame: Day 1, 2 , 5, 6, 10 and 11

  7. Polysomnography (PSG) Objective Assessment of Latency To Persistent Sleep

    Objective assessment: A central scoring facility was used to derive the PSG sleep parameters Latency to Persistent Sleep (LPS) from the epochs and stages collected via the polysomnography (PSG) recordings. Each epoch is 30 seconds. Latency to persistent sleep (LPS; minutes): time from lights out to the first of 20 consecutive epochs (10 minutes) of non-wake, as determined by PSG recordings.

    Time frame: Day 1 to 2, 5 to 6 and 10 to 11

  8. Subjective Assessment of Latency To Persistent Sleep

    Subjective assessment: The amount of time measured in minutes it takes to fall asleep was based on participant-reported subjective assessments of sleep disturbance and was obtained from participants' responses to morning questionnaires.

    Time frame: Women of childbearing potential (WOCBP): Day 2, 11 and follow up visit (Day 13 and 24); Males and women of non-childbearing potential (WONCBP): Day 2, 11, 29 and follow up visit (Day 31 and 42)

  9. PSG Objective Assessment of Total Sleep Time

    Objective assessment: A central scoring facility was used to derive the PSG sleep parameter of Total Sleep Time (TST) from the epochs and stages collected via the PSG recordings. The PSG parameters provided an objective assessment of the subject's sleep on a given night. Total sleep time was defined as the number of non-wake epochs from the beginning of recording to the end of recording divided by 2.

    Time frame: Day 1 to 2, 5 to 6 and 10 to 11

  10. Subjective Assessment of Total Sleep Time

    Subjective assessment: The subjective measure was based on participant-reported subjective assessments of sleep disturbance and were obtained from participants' responses to morning questionnaires.

    Time frame: Women of childbearing potential (WOCBP): Day 2, 11 and follow up visit (Day 13 and 24); Males and women of non-childbearing potential (WONCBP): Day 2, 11, 29 and follow up visit (Day 31 and 42)

  11. PSG Objective Assessment of Wake Time After Sleep Onset (WASO)

    Objective assessment: A central scoring facility was used to derive the PSG sleep parameters Wake Time After Sleep Onset (WASO) from the epochs and stages collected via the PSG recordings. Each epoch is 30 seconds. Wake time after sleep onset (WASO; minutes): The number of wake epochs after the onset of persistent sleep to the end of the recording, divided by 2.

    Time frame: Day 1 to 2, 5 to 6 and 10 to 11

  12. Subjective Assessment of Wake Time After Sleep Onset (WASO)

    Subjective assessment: The subjective measure was based on participant-reported subjective assessments and were obtained from participants' responses to morning questionnaires.

    Time frame: Women of childbearing potential (WOCBP): Day 2, 11 and follow up visit (Day 13 and 24); Males and women of non-childbearing potential (WONCBP): Day 2, 11, 29 and follow up visit (Day 31 and 42)

  13. Inventory of Depressive Symptomatology-clinician Rated 30 (IDSC30) Score and Structured Interview Guide for Hamilton Depression Scale (SIGH-D) (as combined SIGHD-IDS)

    The SIGHD-IDS is a combined structured interview guide to complete both the structured interview guide for the Hamilton Depression Scale (SIGH-D) and the Inventory of depressive symptomatology (IDS-C30). The SIGH-D interview guide is based on the Hamilton Depression Rating Scale (HDRS17; Williams 1988). It contains 17 items pertaining to symptoms of depression experienced over the past week. Score range is from 0 to 52. The IDS-C30 is a standardized 30 item, clinician rated, scale to assess the severity of a participant's depressive symptoms. The scale uses the 9 symptom domains of the Diagnostic and Statistical Manual of Mental Disorders (DSM)-IV criteria to measure symptom severity. The scores range from a minimum of 0 to a maximum score of 84. The higher the score the more severe the symptoms of depression.

    Time frame: Day 1, 11, 29, 31 and 42

  14. Quick Inventory of Depressive Symptoms-16 (QIDS-SR16) Score

    The QIDS-SR16 is a participant reported measure designed to assess the severity of depressive symptoms. Participants provide responses to each item of this instrument with a 4-point Likert scale, with scores ranging from 0-3 for each item. The 7-day period prior to assessment is the usual recall period for assessing symptom severity. The total score ranges from 0 to 27. Using a scale of severity of depression of none, mild, moderate, severe, and very severe, corresponding QIDS-SR16 total scores are none 1-5, mild 6-10, moderate 11-15, severe 16-20 and very severe 21-27.

    Time frame: Day 1, 11, 29, 31 and 42

  15. Ruminative Response Scale (RRS) Score

    Ruminative Response Scale is used to assess symptoms of rumination. It is a 22-item scale. Each item ranges from 1= almost never to 4 = almost always. Total score ranges from 1 to 4.

    Time frame: Day 1, 11 and 29

  16. Changes in Major Depressive Disorder (MDD)-related Biomarkers

    Different biomarkers in blood (Interleukin-6 \[IL-6\]) and saliva (cortisol) will be measured to explore a relation to the seriousness of depressive symptoms or exposure to JNJ-42847922.

    Time frame: Day 1, 11 and 29

  17. Plasma concentrations for JNJ-42847922

    Time frame: Day 1, 2, 6, 11 and 29

07

Study locations

7 sites
  • Aalst, Belgium
  • Brussel, Belgium
  • Duffel, Belgium
  • Berlin, Germany
  • Hamburg, Germany
  • Schwerin, Germany
  • Leiden, Netherlands
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Jun 2015 to primary completion in Jan 2016, 6 months.

Of 40 industry-sponsored phase 1 interventional studies under Depressive Disorder, Major, half reached primary completion within 5 months of starting (the median), counting those still running; a quarter within 1 and three quarters within 12. This study's 6 months is above that.

Counting every sponsor, half of 88 studies reached it within 16 months; a quarter within 5 and three quarters within 45.

How these figures are worked out, and which studies are left out of them.

Registered
May 29, 2015
First posted
Jun 19, 2015
StartActual
Jun 11, 2015
Primary completionActual
Jan 4, 2016
CompletionActual
Jan 4, 2016
Last update
Apr 27, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Apr 27, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT02476058
Responsible party
Sponsor
First posted
Jun 19, 2015
Start date
Jun 11, 2015
Primary completion
Jan 4, 2016
Completion
Jan 4, 2016
Last update
Apr 27, 2025

Study contacts

Janssen-Cilag International NV Clinical Trial
study director · Janssen-Cilag International NV

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Apr 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Seltorexant · Diphenhydramine

Start the discussion